CML (Chronic Myelogenous Leukemia)
Oncology·MeSH: Leukemia, Myelomonocytic, Chronic
Prevalence
5.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| elvn-001 | Enliven Therapeutics, Inc. (ELVN) |
Frequently asked questions
How many drugs are in development for CML (Chronic Myelogenous Leukemia)?
BioSniper tracks 1 drug in development for CML (Chronic Myelogenous Leukemia) across 1 company.
How many clinical trials target CML (Chronic Myelogenous Leukemia)?
There are 2 clinical trials targeting CML (Chronic Myelogenous Leukemia) tracked by BioSniper.
What is the prevalence of CML (Chronic Myelogenous Leukemia)?
The estimated prevalence of CML (Chronic Myelogenous Leukemia) is approximately 5.0 per 100,000 population.
Deep-dive into CML (Chronic Myelogenous Leukemia)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis